文献速递肝病

安慰剂对非酒精性脂肪性肝炎进展与消退的影响:一项Meta分析的证据

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.
PubMed 文献 · Hepatology · 2022-01-24

该Meta分析纳入43项随机对照试验的2649例安慰剂组患者,评估非酒精性脂肪性肝炎(NASH)组织学自然变化。安慰剂组NASH消退且纤维化不恶化的合并比例为11.65%(95%CI:7.98-16.71),NAFLD活动度评分下降≥2分且纤维化不恶化为21.11%(95%CI:17.24-25.57),纤维化改善≥1期为18.82%(95%CI:15.65-22.47),纤维化进展为22.74%(95%CI:19.63-26.17)。

要点

  • 安慰剂组中11.65%的患者出现NASH消退且纤维化不恶化(95%CI:7.98-16.71)。
  • 安慰剂组中21.11%的患者NAFLD活动度评分下降≥2分且纤维化不恶化(95%CI:17.24-25.57)。
  • 安慰剂组纤维化改善≥1期为18.82%(95%CI:15.65-22.47),纤维化进展为22.74%(95%CI:19.63-26.17)。

核心结论

  • 尽管无任何药物干预,相当比例安慰剂组患者肝组织学改善,提示NASH不仅可进展也可随时间自发消退。
  • 安慰剂组组织学应答有助于未来2B期和3期试验设计。

研究设计与样本

  • 研究类型为Meta分析,检索纳入含安慰剂治疗组的NASH随机对照试验(RCT)。
  • 共纳入43项RCT,包含2649例接受安慰剂治疗的患者。
  • 采用广义线性混合模型估计合并比例和均值差异。

主要发现

  • NASH消退且纤维化不恶化的合并比例为11.65%(95%CI:7.98-16.71)。
  • NAFLD活动度评分下降≥2分且纤维化不恶化的合并比例为21.11%(95%CI:17.24-25.57)。
  • 纤维化改善≥1期的比例为18.82%(95%CI:15.65-22.47)。
  • 纤维化进展的比例为22.74%(95%CI:19.63-26.17)。
  • 在安慰剂组患者中,年龄较大和非裔美国人种与较低的NASH消退率相关。

关键数值与推荐

  • NASH消退且纤维化不恶化:合并比例11.65%(95%CI:7.98-16.71)。
  • NAFLD活动度评分下降≥2分且纤维化不恶化:合并比例21.11%(95%CI:17.24-25.57)。
  • 纤维化改善≥1期:合并比例18.82%(95%CI:15.65-22.47)。
  • 纤维化进展:合并比例22.74%(95%CI:19.63-26.17)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The evaluation of the natural history of NASH has been limited. Currently, liver biopsy remains the gold standard in the assessment of NASH. Placebo-controlled trials represent a controlled environment with paired biopsies for the evaluation of NASH. This meta-analysis thus seeks to quantify the change severity of NASH over time, with patients on placebo arms from randomized controlled trials (RCTs) to examine the natural history of NASH. METHODS: A search was conducted to include NASH RCTs with placebo treatment arms. Primary outcomes were (1) the resolution of NASH without worsening of fibrosis, (2) two-point reduction in NAFLD activity score without worsening of fibrosis, and (3) at least one-point reduction in fibrosis. Generalized linear mix model was used to estimate pooled proportion and mean differences. RESULTS: This meta-analysis of 43 RCTs included 2649 placebo-treated patients. The pooled estimate of NASH resolution and two-point NAFLD activity score reduction without worsening of fibrosis was 11.65% (95% CI: 7.98-16.71) and 21.11% (95% CI: 17.24-25.57). The rate of ≥1 stage reduction and progression of fibrosis was 18.82% (95% CI: 15.65-22.47) and 22.74% (CI: 19.63-26.17), respectively. Older age and African American ethnicity was associated with lower NASH resolution rate in placebo-treated patients. CONCLUSIONS: Despite the absence of any pharmacological interventions, a significant proportion of patients in the placebo arm demonstrated improvements in liver histology, highlighting the possibility that NASH is a disease that can not only progress but regress spontaneously over time. Additionally, histologic response in placebo-treated patients is helpful in future design of phase 2B and phase 3 trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ng CH, Xiao J, Lim WH, et al. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology. 2022. PMID: 34990037. doi:10.1002/hep.32315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。